

# FOSUNPHARMA



## BREAS | COMPANY ANNOUNCEMENT

Fosun Pharma concluded its majority investment in Breas on March 16, 2017. The signing ceremony was conducted at head office of Breas in Mölnlycke in presence of executives of Fosun Pharma and PBM Capital, representatives of the city of Gothenburg and Business Region Gothenburg, as well as the entire Breas staff in Sweden. Damian deGoa and Richard Zhao signed the agreements to formalize the partnership and to express their confidence in the bright future of Breas.

Fosun Pharma is now the majority owner of Breas, while PBM Capital remains engaged in the company with a minority share. Both partners are committed to supporting the growth of Breas and to bringing the company to the next level on a bigger global scale.

“With sterling quality and services, the breathing machines of Breas have already established a good reputation and reached a wide range of customers”, remarked Richard Zhao, the Senior Vice President of Fosun Pharma’s Medical Device Department, “We have firm faith in the management team of Breas and give high regards to the Swedish corporate culture of mutual cooperation and support. Amid active cooperation among veteran respiratory experts from Fosun Pharma and the management team of Breas, we’re convinced that Breas will capture a larger market share in the rapidly growing market of China.”

‘We will continue to execute our strategy and 2017 will be an exciting year’, says Damian deGoa, CEO for Breas Medical. ‘This year, we will launch many new products, including a family of world class home care ventilation devices, new sleep apnea devices, a new airway clearance device, and an advanced cloud system for remote patient monitoring. We are investing into our rapidly expanding business in the USA and Fosun Pharma can offer a vast amount of knowledge, market expertise and focus in China, which is a huge opportunity for us. Moreover, Fosun Pharma is a global company with strong financial resources which will help drive Breas’ global expansion’.

The current Breas team will continue to be responsible to serve our customers, clinicians, homecare providers and patients around the world. Fosun Pharma recognizes the importance and strength of the

Breas team as one of the major reasons to invest in the company. The company will continue to be known as and branded as Breas. The new partner, Fosun Pharma will further strengthen Breas and provide resources to achieve the goal to be the leader in home mechanical ventilation.

### About Breas Medical

Breas Medical was founded in 1991 in Mölnlycke, Sweden, as an entrepreneurial company that quickly developed to become one of the global leaders in home mechanical ventilation and sleep treatment. Breas successfully markets the Vivo and iSleep product ranges, the Nippy and Clearway brands, and the Z1 CPAP range, redefining CPAP use in terms of size, weight, and portability.

Breas is a global company selling in more than 40 countries through a network of subsidiaries (Sweden, UK, Spain, Germany, USA) and highly specialized distributors. The 150 Breas employees are the backbone of the company. The employees share their passion for patients and customers which shows in how they approach customer service, product development, manufacturing, sales, marketing, quality and service.

### About Fosun Pharma

Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare Group in the PRC. Fosun Pharma strategically covers important segments of the healthcare industry value-chain, including pharmaceutical manufacturing and R&D, healthcare services, medical diagnosis, medical devices manufacturing and agent, as well as pharmaceutical distribution and retail, making contribution to improving people’s health. Fosun Pharma maintains a National Recognized Enterprise Technology Centre and a highly capable international R&D team, focusing on innovation and research of therapeutic areas including cardiovascular system, central nervous system, blood system, metabolism and alimentary system, anti-infection and anti-tumor. With its commitment to innovation for good health and creating a better future, Fosun Pharma will continue insisting on the strategic development approach of “organic growth, external expansion and integrated development”, striving to be one of the leading enterprises in the global healthcare market.

Complete range in sleep, ventilation and airway clearance



+46 31 86 88 00  
breas@breas.com

**BREAS**